Treatment of ocular cicatricial pemphigoid with the tumour necrosis factor alpha antagonist etanercept [1]

Acta Dermato-Venereologica

Volumn 87, Issue 1, 2007, Pages 74-75

  Prey, Sorilla ^a   Robert, Pierre Yves ^a   Drouet, Mireille ^a   Sparsa, Agnès ^a   Roux, Cyril ^a   Bonnetblanc, Jean Marie ^a   Bédane, Christophe ^a  

^a DUPUYTREN UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DAPSONE; ETANERCEPT; RETINOL; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

AGED; ANAMNESIS; ASTHENIA; CASE REPORT; CONJUNCTIVAL HYPEREMIA; CONJUNCTIVITIS; CORNEA NEOVASCULARIZATION; DRUG TOLERANCE; EYE DISEASE; FEMALE; HEADACHE; HUMAN; IMMUNOBLOTTING; IMMUNOFLUORESCENCE TEST; LETTER; MUCOUS MEMBRANE PEMPHIGOID; NAUSEA AND VOMITING; PRIORITY JOURNAL; TREATMENT RESPONSE; TRICHIASIS;

AGED, 80 AND OVER; EYE DISEASES; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; PEMPHIGOID, BENIGN MUCOUS MEMBRANE; RECEPTORS, TUMOR NECROSIS FACTOR; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33846857347     PISSN: 00015555     EISSN: None     Source Type: Journal    
DOI: 10.2340/00015555-0132     Document Type: Letter

References (14)

1. Chan LS. The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognosis indicator. Arch Dermatol 2002; 138: 370-379.
2. Ahmed M, Zein G, Khawaja F, Foster CS. Ocular cicatricial pemphigoid: pathogenesis, diagnosis and treatment. Prog Retin Eye Res. 2004; 23: 579-592.
3. Liu Z. A passive transfer model of the organ-specific autoimmune disease, bullous pemphigoid, using antibodies generated against the hemidesmosomal antigen, BP180. J Clin Invest 1993: 92; 2480-2488.
4. Lazarova L. Passive transfer of anti-laminin-5 antibodies induces subepidermal blisters in neonatal mice. J Clin Invest 1996; 98: 1509-1518.
5. Lee SJ. Serum levels of tumor necrosis factor-alpha and interleukin-6 in ocular cicatricial pemphigoid. Invest Ophthalmo Vis Sci 1993; 34: 3522-3525.
6. D'Auria L, Mussi A, Bonifati C, Mastroianni A, Giacalone B, Ameglio F. Increased serum IL-6, TNF-alpha and IL-10 levels in patient with bullous pemphigoid: relationships with disease activity. J Eur Acad Dermatol Venereol 1999; 12: 11-15.
7. D'Auria L, Bonifati C, Mussi A, D'Agosto G, De Simone C, Giacalone B, et al. Cytokines in the sera of patients with pemphigus vulgaris: interleukin-6 and tumour necrosis factor-alpha levels are significantly increased as compared to healthy subjects and correlate with disease activity. Eur Cytokine Netw 1997; 8: 383-387.
8. Lopez-Robles E. TNF alpha and IL6 are mediators in the blistering process of pemphigus. Int J Dermatol 2001; 40: 185-188.
9. Berookhim B. Treatment of recalcitrant pemphigus vulgaris with the tumor necrosis factor antagonist etanercept. Cutis 2004; 74: 245-247.
10. Diya F. Management of autoimmune bullous disease. Pharmacology and therapeutics. J Am Acad Dermatol 2004; 51: 859-877.
11. Kirtschig G. Interventions for mucous membrane pemphigoid / mucous membrane pemphigoid and epidermolysis bullosa acquisita: a systematic literature review. Arch Dermatol 2002; 138: 380-384.
12. Banno T. Effects of tumour necrosis factor-alpha (TNF alpha) in epidermal keratinocytes revealed using global transcriptional profiling. J Biol Chem. 2004; 279: 32633-32642.
13. Miserocchi E. The effect of treatment and its related side effects in patients with severe ocular cicatricial pemphigoid. Ophtalmology 2002; 109: 111-118.
14. Sacher C: Treatment of recalcitrant cicatricial pemphigoid with the tumor necrosis factor alpha antagonist etanercept. J Am Acad Dermatol 2002; 46: 113-115.